Articles tagged with Ulcerative Colitis
The majority of potential patients are eager for fecal microbiota transplantation to become available, despite concerns about donor selection and screening. Patients view the treatment as 'natural' and easier than currently available therapies.
Researchers identify IL-23 as a major contributor to inflammation in Crohn's disease and ulcerative colitis, offering hope for new treatments. The study provides insight into the pathogenic role of IL-23 and its potential as a therapeutic target.
A new study has linked 29 genome regions to ulcerative colitis, a common form of inflammatory bowel disease. The research identified genes involved in the immune response and provided insights into the biology underlying the disease.
A new Confocal Laser Endomicroscope (CLE) tool allows clinicians to view bacteria that trigger bowel diseases like Crohn's and ulcerative colitis during routine colonoscopy. This enables rapid identification of patients at risk or in early stages of these diseases.
Researchers discover that infection with Trichuris trichiura eggs increases mucus production in the colon, providing symptomatic relief from ulcerative colitis. The study identifies a shift from pro-inflammatory to anti-inflammatory immune cells, paving the way for potential helminth therapy.
Research found that adults diagnosed with ulcerative colitis at age 50 or later had better disease outcomes, including higher remission rates, compared to those diagnosed earlier in life. The study suggests changes in the aging immune system and environmental factors like smoking may contribute to this phenomenon.
Researchers at McMaster University have identified a chemical, prostaglandin D2, that may trigger remission in patients with ulcerative colitis. Elevated levels of this chemical were found in patients in long-term remission, suggesting it as a key factor in preventing new episodes.
A new study suggests that high protein intake may increase the risk of inflammatory bowel disease, while fatty acids found in olive oil, peanut butter, and grapeseed oil may protect against ulcerative colitis. Additionally, vitamin A supplements have been shown to improve the antiviral effect of treatment drugs for chronic hepatitis C.
A study of over 25,000 people found that those with the highest intake of oleic acid had a significantly lower risk of developing ulcerative colitis. Daily consumption of two-to-three tablespoons of olive oil may help prevent the disease, which affects 120,000 people in the UK.
A meta-analysis published in the World Journal of Gastroenterology suggests that probiotics are an auxiliary medicine for inducing and maintaining remission in ulcerative colitis. The study concluded that probiotics should be considered as a treatment option for this chronic disease.
A new study found that few websites provide high-quality patient information on treatment options for Crohn's disease and ulcerative colitis. Researchers evaluated 50 websites using various criteria to assess their quality and accuracy.
Researchers at Cedars-Sinai Medical Center have identified over 30 regions of the genome linked to ulcerative colitis, providing insights into the disease's causes and potential new therapies. This understanding may lead to more effective treatments tailored to individual patients' needs.
Research found that hospitalization for Crohn's disease was more common among women and younger people, while ulcerative colitis was more common among older people. The study suggests that social deprivation and distance traveled to hospital are associated with Crohn's disease, but not ulcerative colitis.
A Canadian study has found that younger age at diagnosis and more recent year of diagnosis are associated with more severe ulcerative colitis. These findings may help physicians identify patients at higher risk of severe disease and tailor their care accordingly.
Researchers have identified a critical imbalance of regulatory cells and increased 'attack' cells in people with Crohn's disease and ulcerative colitis. This imbalance can be addressed through diet and lifestyle changes, reducing the need for colonoscopies.
Two large-scale genetic studies identified key regions linked to susceptibility in both adult and childhood inflammatory bowel disease, highlighting the role of epithelial defects in creating an 'open door' for bacteria. The findings also suggest potential new targets for treatment by tightening up the mucosal barrier.
Researchers found that retinoic acid reduces inflammation in the colon by increasing FOXP3 expression and decreasing IL-17 levels, which could lead to new treatments for ulcerative colitis. This discovery helps scientists understand what causes and controls inflammation in the colon.
A new study published in the October 2009 issue of Gastroenterology found that patients with moderate-to-severe active ulcerative colitis had a 41 percent reduction in colectomy after one year when treated with infliximab. Treatment with infliximab reduced the incidence of colectomy through 54 weeks by 41 percent.
A new study using SmartPill capsules found that patients with mild to moderate ulcerative colitis have more acidic conditions in their colons compared to healthy individuals. This discovery may impact the effectiveness of mesalamine treatments, which rely on specific pH levels for release.
A study published in Nature Genetics identified genetic markers associated with risk for ulcerative colitis, bringing researchers closer to understanding the biological pathways involved in the disease. The findings may lead to the development of new treatments that specifically target these genes.
Researchers have discovered genetic markers associated with risk for ulcerative colitis, bringing them closer to understanding the biological pathways involved in the disease. The study's findings may lead to the development of new treatments specifically targeting these pathways.
Researchers are investigating the effectiveness of dietary changes and complementary medicine to control inflammatory bowel diseases (IBD) flare-ups. The studies aim to find alternative treatments with fewer side effects, targeting stress reduction and gut bacteria balance.
A post hoc analysis of a study on Lialda revealed significant improvements in time to symptom resolution for patients with mild to moderate ulcerative colitis. The study found that Lialda, an aminosalicylate medication, lowered the time to initial symptom resolution by up to 17 days compared to placebo.
A new analysis of REMICADE for ulcerative colitis found that over 60% of patients achieved clinical response at week 8, with significant improvements maintained at week 30. The study also reported significant improvements in disease remission and mucosal healing.
A study published in the World Journal of Gastroenterology found that patients with inflammatory bowel disease (IBD) in China often receive suboptimal care, including inadequate dosing of aminosalicylates and underuse of immunomodulatory drugs. This is partly due to limited understanding of the disease among Chinese healthcare providers.
A nationwide survey found that nearly three-quarters of UC patients consider feeling unwell normal, while only 37% of gastroenterologists agree. The study highlights the need for improved communication and compliance to address challenges in disease management.
Researchers found that narrow band imaging (NBI) colonoscopy can identify flat dysplastic lesions in ulcerative colitis patients, with a higher positive rate in the tortuous pattern. The study suggests NBI as an alternative to magnifying chromoscopy for cancer surveillance in these patients.
Research reveals MMP-1 and TNF-alpha play a central role in ulcerative colitis development, offering new therapeutic targeting proteins. Agents like Infliximab have shown promise in treating adult and child patients with ulcerative colitis.
A study using a dynamic in vitro gastrointestinal tract system demonstrated that LIALDA tablets release 5-aminosalicylic acid (5-ASA) over a prolonged period in the simulated colon, with nearly 90% of 5-ASA released in the fasted state. In contrast, minimal 5-ASA was released in the stomach and small intestine.
Post-hoc analyses of secondary endpoints from the long-term LIALDA trial show that the medication is effective in maintaining remission in various patient groups, including those with mild and moderate ulcerative colitis. The data also suggest that LIALDA can induce initial symptom resolution within weeks.
Researchers found that mesalamine use among patients with inflammatory bowel disease was associated with a decreased incidence of colorectal cancer. Mesalamine use was linked to an 89% reduction in risk of colorectal cancer, according to the study.
A deficiency of the T-bet protein in dendritic cells has been linked to ulcerative colitis in mice, which can be passed from mother to offspring and between adult animals. This study provides a novel model for the disease, with potential implications for testing new therapies and preventive measures.
A long-term study of REMICADE found that patients with moderate to severe ulcerative colitis maintained improved clinical symptoms for up to two years after treatment. The study showed that 92% of patients had mild or no disease activity at week 56 and 97% at week 104, indicating sustained efficacy.
Long-term study results show that LIALDA (mesalamine) is effective in maintaining remission and preventing relapse in patients with mild to moderate ulcerative colitis. Nearly 9 out of 10 patients on once-daily LIALDA remained relapse free at the end of 12 months.
Researchers have discovered that consuming popcorn may lower the risk of diverticulitis by 28% in individuals with diverticular disease. A randomized clinical trial also found rosiglitazone to be an effective treatment for mild-to-moderately active ulcerative colitis.
UC patients report a heavy psychological toll, with 82% experiencing increased stress and 62% feeling depressed. Nearly four out of five patients worry about long-term health effects, such as colon cancer or surgery. Non-compliance with medication is also a challenge, affecting up to half of patients.
The FDA has approved LIALDA (mesalamine), the first oral once-daily mesalamine for patients with active, mild to moderate ulcerative colitis. Clinical trials found LIALDA effective in inducing remission compared to placebo after eight weeks of treatment.
Research reveals IBD increases risk of premature birth and low birthweight by almost twice, while also boosting caesarean section rates and congenital defects
A CCFA survey reveals that 65% of ulcerative colitis patients are less than fully compliant with first-line therapies, resulting in a significant impact on their quality of life. The most common reasons for non-compliance were dosing frequency, number of pills, and medication inconvenience.
A study by Yale researchers has identified a gene variant associated with Crohn's disease, which may offer new therapeutic targets for the condition. The discovery was made in collaboration with international researchers who scanned the genome of over 300,000 individuals to identify genetic components of inflammatory bowel disease.
Infertility risk in women with ulcerative colitis increases significantly after ileal pouch anal anastomosis surgery, according to a meta-analysis. The study found that the risk of infertility tripled to 48% after the procedure, with no obvious factors contributing to this increased risk.
The Crohn's & Colitis Foundation of America has partnered with John Wiley & Sons, Inc. to publish the peer-reviewed journal Inflammatory Bowel Diseases. The journal will provide a platform for researchers and clinicians to share advances in the treatment and mechanisms of Crohn's disease and ulcerative colitis.
COX-2 inhibitors and other NSAIDs can provide pain relief for patients with dormant inflammatory bowel disease without increasing the risk of flare-ups. Studies show that these medications are tolerated well by IBD patients, despite minimal risks, and can be a safe option for pain management.
A promising new therapy has been approved by the FDA for patients with moderate to severe ulcerative colitis, offering improved lives through reduced inflammation and increased mobility. Nearly 70% of patients experienced clinical response and remission within a year of treatment.
Research suggests that low-dose carbon monoxide can act as an anti-inflammatory agent, reducing the production of interleukin-12 and short-circuiting disease-causing inflammation in ulcerative colitis. Non-smokers with inflammatory bowel disease should not rely on smoking to alleviate symptoms.
The Voices of UC survey highlights the extensive impact of ulcerative colitis on patients' lives, including work, family, and social activities. The study found that nearly half of patients believe their condition is underestimated and misunderstood by others.
A comprehensive analysis of gene expression revealed that 650 genes differ between normal individuals and patients with ulcerative colitis or Crohn disease. Down-regulation, rather than up-regulation, was the prevailing pattern found in both diseases.
Recent clinical trials have shown promising results for biologic therapies in treating Crohn's disease, with Alequel achieving high clinical remission rates. Additionally, a study on adalimumab has demonstrated increased efficacy over time, while maintaining a strong safety profile.
Researchers found statin chemoprevention to be a promising strategy for managing patients with chronic ulcerative colitis, preventing 90-96% of colon cancers. Compared to frequent colonoscopic surveillance, this approach may improve quality of life and reduce costs.
Researchers found that adding a fish oil, soluble fiber, and antioxidant supplement to standard medical therapy significantly reduced the dose of corticosteroids needed to control symptoms. The study provides an alternative treatment option for patients with ulcerative colitis.
Researchers at University of California - San Diego have made a significant breakthrough in treating inflammatory bowel disease by discovering the molecular mechanism behind IFN-α/β therapy. The study reveals that activated IFN-α/β plays a protective role in colonic inflammation and maintains intestinal homeostasis.
Researchers at U-M Health System found that disease severity in patients with ulcerative colitis can be accurately evaluated without frequent lower endoscopies. The study suggests using non-invasive indices, such as patient-reported symptoms, to monitor disease activity and spare patients the discomfort of regular endoscopies.
A study finds that 50% of patients with Crohn's disease have viable MAP in their blood, suggesting a systemic infection. The findings raise questions about the role of MAP in IBD and highlight the need for further research to clarify its significance.
Visilizumab shows promise in treating severe ulcerative colitis by blocking processes that lead to colon inflammation and damage. The new therapy offers an alternative to invasive surgery for patients with severe UC.
Researchers have made significant progress in diagnosing and treating inflammatory bowel diseases (IBD) with new therapies like basiliximab and OPC-6535. These treatments show promise in improving clinical outcomes and reducing symptoms in patients with IBD.
A study published in Inflammatory Bowel Diseases found that gadolinium-enhanced MRI (G-MRI) was highly accurate in diagnosing inflammatory bowel disease (IBD) in children, with 92% accuracy for ulcerative colitis and 96% accuracy for Crohn's disease. This non-invasive diagnostic tool could replace conventional tests like colonoscopy.
Researchers discover a variant of the NFKB1 gene associated with ulcerative colitis, a condition characterized by intestinal inflammation. Additionally, a second study links the MDR1 gene to Crohn's disease and possibly ulcerative colitis.
Researchers identified TL1A, a cytokine that regulates immune response, as a potential target for treating IBD. The protein's expression correlated with inflammation severity in Crohn's disease, but not ulcerative colitis.
A multi-center study found that 63% of patients with mild to moderate ulcerative colitis achieved remission after taking four packets of VSL#3 daily for six weeks. The probiotic composition demonstrated safety and efficacy in patients not responding to conventional therapies.
A randomised controlled trial found that patient-centred self-management training reduced relapse times and hospital visits, while maintaining health-related quality-of-life scores. This alternative approach to traditional outpatient care may improve health-service provision and reduce costs for chronic diseases.